{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:33:47Z","timestamp":1794537227058,"version":"4.9.1"},"reference-count":30,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Insulin icodec is a novel once-weekly basal insulin analog. This trial investigated the efficacy and safety of icodec using different once-weekly titration algorithms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>This was a phase 2, randomized, open-label, 16-week, treat-to-target study. Insulin-naive adults (n = 205) with type 2 diabetes and HbA1c 7\u201310% while treated with oral glucose-lowering medications initiated once-weekly icodec titrations A (prebreakfast self-measured blood glucose target 80\u2013130 mg\/dL; adjustment \u00b121 units\/week; n = 51), B (80\u2013130 mg\/dL; \u00b128 units\/week; n = 51), or C (70\u2013108 mg\/dL; \u00b128 units\/week; n = 52), or once-daily insulin glargine 100 units\/mL (IGlar U100) (80\u2013130 mg\/dL; \u00b14 units\/day; n = 51), all titrated weekly. Percentage of time in range (TIR) (70\u2013180 mg\/dL) during weeks 15 and 16 was measured using continuous glucose monitoring.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>TIR improved from baseline (means: A, 57.0%; B, 55.2%; C, 51.0%; IGlar U100, 55.3%) to weeks 15 and 16 (estimated mean: A, 76.6%; B, 83.0%; C, 80.9%; IGlar U100, 75.9%). TIR was greater for titration B than for IGlar U100 (estimated treatment difference 7.08%-points; 95% CI 2.12 to 12.04; P = 0.005). No unexpected safety signals were observed. Level 2 hypoglycemia (&amp;lt;54 mg\/dL) was low in all groups (0.05, 0.15, 0.38, 0.00 events per patient-year of exposure for icodec titrations A, B, and C and IGlar U100, respectively), with no episodes of severe hypoglycemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Once-weekly icodec was efficacious and well tolerated across all three titration algorithms investigated. The results for icodec titration A (80\u2013130 mg\/dL; \u00b121 units\/week) displayed the best balance between glycemic control and risk of hypoglycemia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc20-2878","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T15:12:18Z","timestamp":1618845138000},"page":"1595-1603","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":82,"title":["A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100"],"prefix":"10.2337","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct03951805","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04460885","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04795531","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04760626","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7006-7401","authenticated-orcid":false,"given":"Ildiko","family":"Lingvay","sequence":"first","affiliation":[{"name":"Endocrinology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX"},{"name":"Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Buse","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Franek","sequence":"additional","affiliation":[{"name":"Mossakowski Medical Research Centre, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa V.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette M.","family":"Koefoed","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6099-2406","authenticated-orcid":false,"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Pettus","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Stachlewska","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-3275","authenticated-orcid":false,"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes Research Center at Medical City, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"2022051617201114300_B1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13300-018-0421-5","article-title":"Adherence to basal insulin therapy among people with type 2 diabetes: a retrospective cohort study of costs and patient outcomes","volume":"9","author":"Perez-Nieves","year":"2018","journal-title":"Diabetes Ther"},{"key":"2022051617201114300_B2","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","article-title":"Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study","volume":"28","author":"Peyrot","year":"2005","journal-title":"Diabetes Care"},{"key":"2022051617201114300_B3","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2147\/PPA.S106821","article-title":"Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors","volume":"10","author":"Polonsky","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2022051617201114300_B4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2337\/diaspect.29.3.166","article-title":"Adherence to insulin therapy","volume":"29","author":"Sarbacker","year":"2016","journal-title":"Diabetes Spectr"},{"key":"2022051617201114300_B5","first-page":"36","article-title":"AADE practice paper in brief: diabetes educators play a critical role in successful insulin management","volume":"6","author":"Yehl","year":"2018","journal-title":"AADE Pract"},{"key":"2022051617201114300_B6","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"2022051617201114300_B7","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/dom.13603","article-title":"Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States","volume":"21","author":"Mody","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2022051617201114300_B8","doi-asserted-by":"crossref","first-page":"154190","DOI":"10.1016\/j.metabol.2020.154190","article-title":"Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies","volume":"106","author":"Morieri","year":"2020","journal-title":"Metabolism"},{"key":"2022051617201114300_B9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1463-1326.2010.01327.x","article-title":"Patient perspectives on once-weekly medications for diabetes","volume":"13","author":"Polonsky","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022051617201114300_B10","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12325-016-0470-y","article-title":"Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a Medicare population","volume":"34","author":"Nguyen","year":"2017","journal-title":"Adv Ther"},{"key":"2022051617201114300_B11","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1464-5491.2009.02752.x","article-title":"Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily","volume":"26","author":"Best","year":"2009","journal-title":"Diabet Med"},{"key":"2022051617201114300_B12","doi-asserted-by":"crossref","first-page":"236-OR","DOI":"10.2337\/db20-236-OR","article-title":"Molecular and biological properties of insulin icodec, a new insulin analog designed to give a long half-life suitable for once-weekly dosing (Abstract)","volume":"69","author":"Nishimura","year":"2020","journal-title":"Diabetes"},{"key":"2022051617201114300_B13","doi-asserted-by":"crossref","first-page":"237-OR","DOI":"10.2337\/db20-237-OR","article-title":"Insulin icodec: an insulin analog suited for once-weekly dosing in type 2 diabetes (Abstract)","volume":"69","author":"H\u00f6velmann","year":"2020","journal-title":"Diabetes"},{"key":"2022051617201114300_B14","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa2022474","article-title":"Once-weekly insulin for type 2 diabetes without previous insulin treatment","volume":"383","author":"Rosenstock","year":"2020","journal-title":"N Engl J Med"},{"key":"2022051617201114300_B15","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.2337\/dc18-S006","article-title":"6. Glycemic targets: Standards of Medical Care in Diabetes\u20142018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"2022051617201114300_B16","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00125-007-0911-x","article-title":"A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"51","author":"Rosenstock","year":"2008","journal-title":"Diabetologia"},{"key":"2022051617201114300_B17","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"2022051617201114300_B18","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/dom.13804","article-title":"Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: the PIONEER 1 randomized clinical trial as an example","volume":"21","author":"Aroda","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2022051617201114300_B19","volume-title":"Statistical Analysis With Missing Data","author":"Little","year":"1987"},{"key":"2022051617201114300_B20","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2337\/dc09-2294","article-title":"A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs","volume":"33","author":"Swinnen","year":"2010","journal-title":"Diabetes Care"},{"key":"2022051617201114300_B21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/dom.12032","article-title":"Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials","volume":"15","author":"Ratner","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022051617201114300_B22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/dia.2019.0251","article-title":"Time in range is associated with carotid intima-media thickness in type 2 diabetes","volume":"22","author":"Lu","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"2022051617201114300_B23","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2337\/dc18-1131","article-title":"Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes","volume":"41","author":"Lu","year":"2018","journal-title":"Diabetes Care"},{"key":"2022051617201114300_B24","doi-asserted-by":"crossref","first-page":"e000991","DOI":"10.1136\/bmjdrc-2019-000991","article-title":"Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease","volume":"8","author":"Mayeda","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2022051617201114300_B25","doi-asserted-by":"crossref","first-page":"5817074","DOI":"10.1155\/2020\/5817074","article-title":"Time in range, as a novel metric of glycemic control, is reversely associated with presence of diabetic cardio-vascular autonomic neuropathy independent of HbA1c in Chinese type 2 diabetes","volume":"2020","author":"Guo","year":"2020","journal-title":"J Diabetes Res"},{"key":"2022051617201114300_B26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2337\/dc20-1862","article-title":"Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study","volume":"44","author":"Lu","year":"2021","journal-title":"Diabetes Care"},{"key":"2022051617201114300_B27","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.2337\/dc20-0909","article-title":"Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes","volume":"43","author":"Ranjan","year":"2020","journal-title":"Diabetes Care"},{"key":"2022051617201114300_B28","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/1932296818822496","article-title":"The relationships between time in range, hyper-glycemia metrics, and HbA1c","volume":"13","author":"Beck","year":"2019","journal-title":"J Diabetes Sci Technol"},{"key":"2022051617201114300_B29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/dia.2018.0310","article-title":"The relationship of hemoglobin A1C to time-in-range in patients with diabetes","volume":"21","author":"Vigersky","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"2022051617201114300_B30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc20-2878","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/7\/1595\/633046\/dc202878.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/7\/1595\/633046\/dc202878.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T17:20:44Z","timestamp":1652721644000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/44\/7\/1595\/138812\/A-Randomized-Open-Label-Comparison-of-Once-Weekly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4,19]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc20-2878","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]}}}